ArticleJACC. Asia2025
Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Who cites it
7 citing papers in PubMed.
- Imaging-Based Risk Stratification for Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Current Evidence and Clinical Perspectives.Medical sciences (Basel, Switzerland) · 2026Review
- Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.Journal of the American Heart Association · 2026Article
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy.ESC heart failure · 2026Article
- Prediction model for early left ventricular systolic dysfunction progression in hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2026Article
- Mavacamten in Symptomatic Hypertrophic Cardiomyopathy: A Paradigm Shift or Revolution?JACC. Asia · 2025Article
- Cardiac magnetic resonance research advances in myocardial fibrosis of hypertrophic cardiomyopathy.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMavacamten, a first-in-class cardiac myosin inhibitor and the only approved cardiac myosin inhibitor worldwide, improved clinical symptoms and health status in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in phase 3 EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545) and EXPLORER-CN (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM; NCT05174416).
objectivesThe purpose of this work was to study the effect of mavacamten on cardiac structure and function by cardiac magnetic resonance (CMR) imaging in Chinese participants in EXPLORER-CN.
methodsEligible patients with obstructive HCM underwent CMR imaging at screening and week 30. Change from baseline to week 30 in left ventricular (LV) mass index was analyzed as a prespecified secondary outcome. Prespecified exploratory outcomes included changes in cellular hypertrophy, cardiac structure and function, and myocardial fibrosis by CMR.
resultsAmong 81 patients randomized, 58 patients (mean age 51.2 years, 74.1% men) with CMR data available were analyzed (mavacamten, n = 39; placebo, n = 19). After 30 weeks, greater reductions from baseline were observed (mean between-group difference) with mavacamten vs placebo in LV mass index (-30.8 g/m
conclusionsAt 30 weeks, improvements were observed in measures of cardiac structure and function, with reductions in indicators of myocardial fibrosis, in the mavacamten vs the placebo group. (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM; NCT05174416).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.